NASDAQ:SEEL

Seelos Therapeutics Competitors

$5.36
+0.23 (+4.48 %)
(As of 05/7/2021 12:00 AM ET)
Add
Compare
Today's Range
$5.06
$5.48
50-Day Range
$3.85
$6.32
52-Week Range
$0.56
$6.60
Volume2.44 million shs
Average Volume8.15 million shs
Market Capitalization$421.60 million
P/E RatioN/A
Dividend YieldN/A
Beta2.36

Competitors

Seelos Therapeutics (NASDAQ:SEEL) Vs. SAVA, ADCT, AMTI, HRMY, PMVP, and AMRX

Should you be buying SEEL stock or one of its competitors? Companies in the industry of "pharmaceutical preparations" are considered alternatives and competitors to Seelos Therapeutics, including Cassava Sciences (SAVA), ADC Therapeutics (ADCT), Applied Molecular Transport (AMTI), Harmony Biosciences (HRMY), PMV Pharmaceuticals (PMVP), and Amneal Pharmaceuticals (AMRX).

Cassava Sciences (NASDAQ:SAVA) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk and valuation.

Analyst Ratings

This is a summary of recent ratings and target prices for Cassava Sciences and Seelos Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Cassava Sciences00503.00
Seelos Therapeutics00303.00

Cassava Sciences currently has a consensus price target of $46.00, indicating a potential upside of 11.03%. Seelos Therapeutics has a consensus price target of $13.6667, indicating a potential upside of 154.74%. Given Seelos Therapeutics' higher possible upside, analysts clearly believe Seelos Therapeutics is more favorable than Cassava Sciences.

Institutional & Insider Ownership

26.7% of Cassava Sciences shares are held by institutional investors. Comparatively, 9.3% of Seelos Therapeutics shares are held by institutional investors. 13.7% of Cassava Sciences shares are held by insiders. Comparatively, 7.6% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Risk & Volatility

Cassava Sciences has a beta of 1.47, suggesting that its stock price is 47% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 2.36, suggesting that its stock price is 136% more volatile than the S&P 500.

Earnings & Valuation

This table compares Cassava Sciences and Seelos Therapeutics' gross revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Cassava SciencesN/AN/A$-4,630,000.00($0.27)-153.44
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A

Cassava Sciences has higher earnings, but lower revenue than Seelos Therapeutics.

Profitability

This table compares Cassava Sciences and Seelos Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Cassava SciencesN/A-22.01%-20.85%
Seelos TherapeuticsN/A-543.45%-217.32%

Summary

Cassava Sciences beats Seelos Therapeutics on 6 of the 9 factors compared between the two stocks.

Seelos Therapeutics (NASDAQ:SEEL) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seelos Therapeutics and ADC Therapeutics, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seelos Therapeutics00303.00
ADC Therapeutics01402.80

Seelos Therapeutics currently has a consensus price target of $13.6667, indicating a potential upside of 154.74%. ADC Therapeutics has a consensus price target of $49.75, indicating a potential upside of 110.89%. Given Seelos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seelos Therapeutics is more favorable than ADC Therapeutics.

Institutional and Insider Ownership

9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 40.9% of ADC Therapeutics shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Seelos Therapeutics and ADC Therapeutics' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A
ADC Therapeutics$2.34 million694.51$-116,480,000.00($2.36)-10.00

Seelos Therapeutics has higher earnings, but lower revenue than ADC Therapeutics.

Profitability

This table compares Seelos Therapeutics and ADC Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seelos TherapeuticsN/A-543.45%-217.32%
ADC TherapeuticsN/AN/AN/A

Seelos Therapeutics (NASDAQ:SEEL) and Applied Molecular Transport (NASDAQ:AMTI) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seelos Therapeutics and Applied Molecular Transport, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seelos Therapeutics00303.00
Applied Molecular Transport00403.00

Seelos Therapeutics currently has a consensus price target of $13.6667, indicating a potential upside of 154.74%. Applied Molecular Transport has a consensus price target of $68.75, indicating a potential upside of 50.04%. Given Seelos Therapeutics' higher possible upside, analysts plainly believe Seelos Therapeutics is more favorable than Applied Molecular Transport.

Institutional and Insider Ownership

9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 52.0% of Applied Molecular Transport shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Seelos Therapeutics and Applied Molecular Transport's revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A
Applied Molecular TransportN/AN/A$-28,040,000.00N/AN/A

Applied Molecular Transport has lower revenue, but higher earnings than Seelos Therapeutics.

Profitability

This table compares Seelos Therapeutics and Applied Molecular Transport's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seelos TherapeuticsN/A-543.45%-217.32%
Applied Molecular TransportN/AN/AN/A

Summary

Applied Molecular Transport beats Seelos Therapeutics on 5 of the 8 factors compared between the two stocks.

Seelos Therapeutics (NASDAQ:SEEL) and Harmony Biosciences (NASDAQ:HRMY) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Analyst Recommendations

This is a summary of recent ratings and price targets for Seelos Therapeutics and Harmony Biosciences, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seelos Therapeutics00303.00
Harmony Biosciences00303.00

Seelos Therapeutics currently has a consensus price target of $13.6667, indicating a potential upside of 154.74%. Harmony Biosciences has a consensus price target of $51.6667, indicating a potential upside of 86.39%. Given Seelos Therapeutics' higher possible upside, analysts plainly believe Seelos Therapeutics is more favorable than Harmony Biosciences.

Institutional and Insider Ownership

9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 50.2% of Harmony Biosciences shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Earnings and Valuation

This table compares Seelos Therapeutics and Harmony Biosciences' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A
Harmony BiosciencesN/AN/AN/AN/AN/A

Harmony Biosciences has lower revenue, but higher earnings than Seelos Therapeutics.

Profitability

This table compares Seelos Therapeutics and Harmony Biosciences' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seelos TherapeuticsN/A-543.45%-217.32%
Harmony BiosciencesN/AN/AN/A

Seelos Therapeutics (NASDAQ:SEEL) and PMV Pharmaceuticals (NASDAQ:PMVP) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their institutional ownership, earnings, profitability, risk, analyst recommendations, valuation and dividends.

Earnings and Valuation

This table compares Seelos Therapeutics and PMV Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A
PMV PharmaceuticalsN/AN/AN/AN/AN/A

PMV Pharmaceuticals has lower revenue, but higher earnings than Seelos Therapeutics.

Institutional and Insider Ownership

9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 69.7% of PMV Pharmaceuticals shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Profitability

This table compares Seelos Therapeutics and PMV Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seelos TherapeuticsN/A-543.45%-217.32%
PMV PharmaceuticalsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings and price targets for Seelos Therapeutics and PMV Pharmaceuticals, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seelos Therapeutics00303.00
PMV Pharmaceuticals01302.75

Seelos Therapeutics currently has a consensus price target of $13.6667, indicating a potential upside of 154.74%. PMV Pharmaceuticals has a consensus price target of $38.00, indicating a potential upside of 8.57%. Given Seelos Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Seelos Therapeutics is more favorable than PMV Pharmaceuticals.

Summary

Seelos Therapeutics beats PMV Pharmaceuticals on 4 of the 7 factors compared between the two stocks.

Seelos Therapeutics (NASDAQ:SEEL) and Amneal Pharmaceuticals (NYSE:AMRX) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their dividends, risk, analyst recommendations, earnings, profitability, institutional ownership and valuation.

Earnings & Valuation

This table compares Seelos Therapeutics and Amneal Pharmaceuticals' revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Seelos Therapeutics$380,000.001,109.47$-51,260,000.00N/AN/A
Amneal Pharmaceuticals$1.63 billion0.96$-361,920,000.00$0.2719.26

Seelos Therapeutics has higher earnings, but lower revenue than Amneal Pharmaceuticals.

Volatility and Risk

Seelos Therapeutics has a beta of 2.36, meaning that its stock price is 136% more volatile than the S&P 500. Comparatively, Amneal Pharmaceuticals has a beta of 1.27, meaning that its stock price is 27% more volatile than the S&P 500.

Insider & Institutional Ownership

9.3% of Seelos Therapeutics shares are owned by institutional investors. Comparatively, 33.5% of Amneal Pharmaceuticals shares are owned by institutional investors. 7.6% of Seelos Therapeutics shares are owned by company insiders. Comparatively, 26.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Seelos Therapeutics and Amneal Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Seelos TherapeuticsN/A-543.45%-217.32%
Amneal Pharmaceuticals3.30%42.02%3.82%

Analyst Ratings

This is a breakdown of recent recommendations for Seelos Therapeutics and Amneal Pharmaceuticals, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Seelos Therapeutics00303.00
Amneal Pharmaceuticals01502.83

Seelos Therapeutics currently has a consensus target price of $13.6667, indicating a potential upside of 154.74%. Amneal Pharmaceuticals has a consensus target price of $7.00, indicating a potential upside of 34.62%. Given Seelos Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Seelos Therapeutics is more favorable than Amneal Pharmaceuticals.

Summary

Amneal Pharmaceuticals beats Seelos Therapeutics on 7 of the 12 factors compared between the two stocks.


Seelos Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
Cassava Sciences logo
SAVA
Cassava Sciences
1.1$41.43+0.9%$1.66 billionN/A-172.63Analyst Revision
ADC Therapeutics logo
ADCT
ADC Therapeutics
1.7$23.59+4.2%$1.63 billion$2.34 million-10.00Earnings Announcement
Unusual Options Activity
News Coverage
Gap Down
Applied Molecular Transport logo
AMTI
Applied Molecular Transport
2.0$45.82+3.0%$1.62 billionN/A0.00News Coverage
Harmony Biosciences logo
HRMY
Harmony Biosciences
1.4$27.72+1.1%$1.58 billionN/A0.00Upcoming Earnings
PMV Pharmaceuticals logo
PMVP
PMV Pharmaceuticals
1.2$35.00+0.3%$1.57 billionN/A0.00Insider Selling
Amneal Pharmaceuticals logo
AMRX
Amneal Pharmaceuticals
2.0$5.20+11.2%$1.56 billion$1.63 billion12.68Earnings Announcement
Analyst Upgrade
News Coverage
Gap Up
Supernus Pharmaceuticals logo
SUPN
Supernus Pharmaceuticals
1.9$29.37+0.3%$1.56 billion$392.76 million12.19Earnings Announcement
Analyst Revision
Heron Therapeutics logo
HRTX
Heron Therapeutics
1.7$16.63+0.5%$1.52 billion$145.97 million-6.73Upcoming Earnings
Analyst Downgrade
Analyst Revision
uniQure logo
QURE
uniQure
1.7$32.55+1.0%$1.49 billion$7.28 million-8.63Upcoming Earnings
Analyst Revision
Y-mAbs Therapeutics logo
YMAB
Y-mAbs Therapeutics
1.6$34.20+16.2%$1.49 billionN/A-11.52Earnings Announcement
Analyst Upgrade
High Trading Volume
Decrease in Short Interest
News Coverage
Gap Down
Prelude Therapeutics logo
PRLD
Prelude Therapeutics
1.6$41.61+1.9%$1.48 billionN/A0.00Analyst Upgrade
Gap Down
ImmunoGen logo
IMGN
ImmunoGen
1.5$7.33+3.4%$1.47 billion$82.27 million-17.88Upcoming Earnings
Kronos Bio logo
KRON
Kronos Bio
1.7$25.69+0.8%$1.44 billionN/A0.00Increase in Short Interest
Gap Down
Zymeworks logo
ZYME
Zymeworks
1.6$30.30+2.7%$1.40 billion$29.54 million-8.04Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Zealand Pharma A/S logo
ZEAL
Zealand Pharma A/S
1.2$32.05+3.5%$1.39 billion$6.20 million-14.06Upcoming Earnings
Endo International logo
ENDP
Endo International
1.5$5.63+3.6%$1.31 billion$2.91 billion-8.28Earnings Announcement
Analyst Downgrade
Analyst Revision
News Coverage
Aurinia Pharmaceuticals logo
AUPH
Aurinia Pharmaceuticals
1.5$10.15+21.7%$1.30 billion$320,000.00-6.90Earnings Announcement
Analyst Report
High Trading Volume
Analyst Revision
News Coverage
Gap Up
Theravance Biopharma logo
TBPH
Theravance Biopharma
1.6$19.75+1.8%$1.29 billion$73.41 million-4.18Earnings Announcement
Analyst Report
Analyst Revision
Protagonist Therapeutics logo
PTGX
Protagonist Therapeutics
1.5$29.18+4.0%$1.28 billion$230,000.00-13.57Earnings Announcement
High Trading Volume
Analyst Revision
Gap Down
COMPASS Pathways logo
CMPS
COMPASS Pathways
1.4$34.07+1.7%$1.25 billionN/A0.00Upcoming Earnings
Gap Up
Keros Therapeutics logo
KROS
Keros Therapeutics
1.5$53.11+2.3%$1.24 billionN/A0.00Earnings Announcement
Analyst Downgrade
Insider Selling
Gap Up
Ocular Therapeutix logo
OCUL
Ocular Therapeutix
1.6$16.25+2.3%$1.24 billion$4.23 million-9.08Earnings Announcement
High Trading Volume
Analyst Revision
News Coverage
Gap Down
Avid Bioservices logo
CDMO
Avid Bioservices
1.7$20.30+1.6%$1.23 billion$59.70 million-203.00
Shattuck Labs logo
STTK
Shattuck Labs
1.5$29.52+8.4%$1.23 billionN/A0.00Gap Up
Repare Therapeutics logo
RPTX
Repare Therapeutics
1.6$33.07+2.1%$1.22 billionN/A0.00
Travere Therapeutics logo
TVTX
Travere Therapeutics
1.3$20.01+17.4%$1.21 billion$175.34 million-11.77Earnings Announcement
Analyst Report
News Coverage
Gap Up
Aclaris Therapeutics logo
ACRS
Aclaris Therapeutics
0.8$22.95+3.8%$1.20 billion$4.23 million-17.00Earnings Announcement
Analyst Upgrade
Insider Selling
Analyst Revision
News Coverage
Gap Up
Stoke Therapeutics logo
STOK
Stoke Therapeutics
1.4$32.46+3.3%$1.19 billionN/A-18.03Analyst Revision
News Coverage
Gap Down
Innoviva logo
INVA
Innoviva
1.1$11.73+1.8%$1.19 billion$261.02 million5.98Analyst Upgrade
Gap Down
Pliant Therapeutics logo
PLRX
Pliant Therapeutics
2.0$32.90+3.6%$1.18 billion$57.05 million0.00Gap Down
Humanigen logo
HGEN
Humanigen
1.7$19.36+5.0%$1.14 billionN/A0.00Analyst Report
Analyst Revision
Gap Down
Dynavax Technologies logo
DVAX
Dynavax Technologies
1.7$9.81+9.5%$1.12 billion$35.22 million-7.16Earnings Announcement
News Coverage
Gap Down
Rhythm Pharmaceuticals logo
RYTM
Rhythm Pharmaceuticals
1.8$22.12+2.8%$1.11 billionN/A-7.28Earnings Announcement
Gap Down
Phibro Animal Health logo
PAHC
Phibro Animal Health
1.7$27.45+5.9%$1.11 billion$800.40 million25.90Earnings Announcement
Dividend Announcement
High Trading Volume
News Coverage
Gap Down
Omeros logo
OMER
Omeros
1.4$17.75+1.1%$1.11 billion$111.81 million-7.46Upcoming Earnings
Analyst Upgrade
Analyst Revision
Phathom Pharmaceuticals logo
PHAT
Phathom Pharmaceuticals
1.8$34.96+3.7%$1.10 billionN/A-2.50Upcoming Earnings
Insider Selling
News Coverage
Praxis Precision Medicines logo
PRAX
Praxis Precision Medicines
1.7$28.06+1.6%$1.08 billionN/A0.00
MannKind logo
MNKD
MannKind
1.4$4.29+4.9%$1.07 billion$63.04 million-20.43Upcoming Earnings
Analyst Downgrade
Analyst Revision
Gap Down
Mersana Therapeutics logo
MRSN
Mersana Therapeutics
1.2$15.42+3.3%$1.06 billion$42.12 million-11.42Upcoming Earnings
Gap Down
Zogenix logo
ZGNX
Zogenix
1.7$18.87+7.1%$1.05 billion$3.65 million-1.98Earnings Announcement
Analyst Revision
News Coverage
Gap Down
ESSA Pharma logo
EPIX
ESSA Pharma
1.4$29.73+0.8%$1.00 billionN/A-27.53Earnings Announcement
Analyst Revision
News Coverage
Kiniksa Pharmaceuticals logo
KNSA
Kiniksa Pharmaceuticals
1.7$14.63+0.1%$998.23 millionN/A-6.17Earnings Announcement
Analyst Upgrade
Analyst Revision
News Coverage
Constellation Pharmaceuticals logo
CNST
Constellation Pharmaceuticals
1.2$20.80+1.2%$996.61 millionN/A-7.68Upcoming Earnings
Vanda Pharmaceuticals logo
VNDA
Vanda Pharmaceuticals
1.5$17.86+2.0%$992.34 million$227.19 million49.61Earnings Announcement
Analyst Revision
News Coverage
Trillium Therapeutics logo
TRIL
Trillium Therapeutics
1.7$9.59+3.1%$988.09 million$120,000.00-3.55Earnings Announcement
Gap Down
Prothena logo
PRTA
Prothena
1.9$24.62+3.9%$984.95 million$810,000.00-9.62Upcoming Earnings
Analyst Revision
Gap Down
Enanta Pharmaceuticals logo
ENTA
Enanta Pharmaceuticals
1.4$48.50+5.2%$978.34 million$122.47 million-26.65Earnings Announcement
News Coverage
Gap Up
Radius Health logo
RDUS
Radius Health
1.1$20.60+1.6%$973.14 million$173.32 million-8.44Earnings Announcement
News Coverage
Affimed logo
AFMD
Affimed
1.6$9.81+1.1%$964.20 million$23.96 million-16.63
Dyne Therapeutics logo
DYN
Dyne Therapeutics
1.5$18.71+3.2%$962.85 millionN/A0.00Earnings Announcement
Analyst Downgrade
News Coverage
Gap Down
This page was last updated on 5/8/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.